Purine nucleotide cycle in rat renal cortex and medulla under conditions that mimic normal and low oxygen supply.
The distinctive feature of the renal function and metabolism implicate a possibility of excessive ATP degradation during insufficient oxygen supply. Protection of the purine ring against degradation is one among other functions of the purine nucleotide cycle (PNC). The purpose of this study was to estimate the activity of PNC in cytosol of rat renal cortex and medulla under conditions that mimic normal and low oxygen supply in vivo. In normoxic-like condition the rate of AMP deamination was 1.7 and 2.0 nmol/mg protein/min in the cytosol of cortex and medulla, respectively. Under this condition, the rate of IMP reamination was similar to that of AMP deamination. In a hypoxia-like condition the rate of AMP deamination increased by 41% in cytosol from both parts of the kidney, while the rate of IMP reamination remained unchanged in the cytosol of medulla and decreased by 46% in the cortex cytosol. Distribution of the other enzymes of the PNC, that is, adenylosuccinate synthetase and adenylosuccinate lyase, in the cytosol of cortex and medulla correlated with that observed for AMP deamination and IMP reamination potentials. At 150 microM IMP, the activity of adenylosuccinate synthetase in the cortex and medulla was 0.34 and 1.24 nmol/mg protein/min, respectively. Activity of the adenylosuccinate lyase was severalfold greater than the respective activity of the adenylosuccinate synthetase. These results show that the efficiency of PNC is about twice as high in the medulla cytosol as in the cortex cytosol, and that the activity of PNC in kidney is mainly limited by the activity of adenylosuccinate synthetase and supply of AMP.
Stepinski
J
J
Department of Clinical Biochemistry, Medical University of Gdansk, Poland.
Pawelczyk
T
T
Bizon
D
D
Angielski
S
S
D000227:Adenine Nucleotides / Q000378:metabolism; D000264:Adenylosuccinate Lyase / Q000493:pharmacokinetics; D000265:Adenylosuccinate Synthase / Q000493:pharmacokinetics; D000586:Amination / Q000187:drug effects; D000641:Ammonia / Q000378:metabolism; D000818:Animals; D003070:Coformycin / Q000494:pharmacology; D003641:Deamination / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D000860:Hypoxia / Q000378:metabolism*; D007672:Kidney Cortex / Q000187:drug effects / Q000378:metabolism*; D007679:Kidney Medulla / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D011685:Purine Nucleotides / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D000227:Adenine Nucleotides; D011685:Purine Nucleotides; D003070:Coformycin; D000641:Ammonia; D000264:Adenylosuccinate Lyase; D000265:Adenylosuccinate Synthase